Sophiris bio inc. (SPHS)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
License revenue

-

-

-

-

-

5,000

-

-

Operating expenses:
Research and development

10,710

6,186

3,538

9,862

24,708

10,279

13,523

8,660

General and administrative

4,429

5,732

6,768

3,626

5,332

4,511

5,685

4,635

Total operating expenses

15,139

11,918

10,306

13,488

30,040

14,790

19,208

13,295

Other income (expense):
Interest expense

684

207

373

690

726

1,308

1,988

895

Interest income

333

238

37

22

51

0

108

-

Gain on revaluation of warrant liability

8,690

3,307

-330

0

49

689

-

-

Loss on early extinguishment of debt

-

-

-180

0

0

-

-

-

Other income (expense), net

22

-48

-12

-41

-46

-240

-106

-11

Total other income (expense)

8,361

3,290

-858

-709

-672

-859

-1,986

-906

Net loss before income taxes

-

-

-

-

-

-10,649

-21,194

-14,201

Income tax expense

-

-

-

-

-

500

-

-

Net loss

-6,778

-8,628

-11,164

-14,197

-30,712

-11,149

-21,194

-14,201

Basic and diluted loss per share (in dollars per share)

-0.23

-0.29

-0.49

-0.84

-1.85

-1.39

-6.94

-6.05

Weighted average number of outstanding shares – basic and diluted (in shares)

30,115

30,111

23,002

16,881

16,586

8,029

3,054

2,345

Other comprehensive loss:
Foreign currency translation adjustment

-

-

-

-

-

145

131

14

Unrealized income on securities available-for-sale

3

-2

-

0

1

-1

-

-

Total other comprehensive loss

-6,775

-8,630

-11,164

-14,197

-30,711

-11,005

-21,063

-14,187